Greg Stanley

Greg Stanley has a diverse work experience in the healthcare industry. Greg started their career in sales and marketing at Abbott Laboratories in 1987. Greg later worked at Chiron Corporation as an Area Business Manager before joining Radiometer America as Vice President of Sales. At Radiometer America, they led a 100-member sales/service organization and managed the company's commercial operations.

In 2001, Stanley moved to Roche Diagnostics where they served as the Director of Marketing and National Director of Corporate Accounts. Greg was responsible for directing sales, managing P&Ls, and developing strategic and tactical plans. Greg also led a multi-divisional sales and marketing organization and managed sales on a corporate basis to Novation's healthcare membership.

Stanley then joined Oncimmune in 2007 as Chief Commercial Officer, where they focused on the early detection of cancer. During their tenure, they played a crucial role in developing the company's proprietary molecular platform and expanding its early detection capabilities.

In 2014, Stanley joined OPKO Health Inc. as Vice President of Sales and Marketing for the Global Diagnostics Business Unit. Here, they utilized their discovery, development, and commercialization expertise to establish OPKO's industry-leading positions in biopharmaceutical and diagnostics markets.

In 2015, Stanley joined Oncimmune Limited & EarlyCDT-Lung as President of Commercial Operations. Greg continued to contribute to early cancer detection efforts and oversaw the company's commercial operations.

Their most recent role is as Chief Commercial Officer at TechLab, Inc., a private equity-owned company.

Greg Stanley has a Bachelor of Science (B.S.) degree in Business Administration, Management & Marketing from the University of Missouri-Saint Louis. The specific start and end years of their education are not provided.